These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Taksin AL; Couedic JP; Dusanter-Fourt I; Massé A; Giraudier S; Katz A; Wendling F; Vainchenker W; Casadevall N; Debili N Blood; 1999 Jan; 93(1):125-39. PubMed ID: 9864154 [TBL] [Abstract][Full Text] [Related]
10. SET domain containing 2 promotes megakaryocyte polyploidization and platelet generation through methylation of α-tubulin. Chen L; Liu J; Chen K; Su Y; Chen Y; Lei Y; Si J; Zhang J; Zhang Z; Zou W; Zhang X; Rondina MT; Wang QF; Li Y J Thromb Haemost; 2024 Jun; 22(6):1727-1741. PubMed ID: 38537781 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation. Machlus KR; Wu SK; Stumpo DJ; Soussou TS; Paul DS; Campbell RA; Kalwa H; Michel T; Bergmeier W; Weyrich AS; Blackshear PJ; Hartwig JH; Italiano JE Blood; 2016 Mar; 127(11):1468-80. PubMed ID: 26744461 [TBL] [Abstract][Full Text] [Related]
12. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702 [TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Raslova H; Baccini V; Loussaief L; Comba B; Larghero J; Debili N; Vainchenker W Blood; 2006 Mar; 107(6):2303-10. PubMed ID: 16282343 [TBL] [Abstract][Full Text] [Related]
14. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315 [TBL] [Abstract][Full Text] [Related]
15. Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation. Mazharian A; Watson SP; Séverin S Exp Hematol; 2009 Oct; 37(10):1238-1249.e5. PubMed ID: 19619605 [TBL] [Abstract][Full Text] [Related]
16. Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice. Barbieri SS; Petrucci G; Tarantino E; Amadio P; Rocca B; Pesce M; Machlus KR; Ranelletti FO; Gianellini S; Weksler B; Italiano JE; Tremoli E Thromb Haemost; 2015 Nov; 114(6):1218-29. PubMed ID: 26272103 [TBL] [Abstract][Full Text] [Related]
18. Don't you forget about me(gakaryocytes). Tilburg J; Becker IC; Italiano JE Blood; 2022 Jun; 139(22):3245-3254. PubMed ID: 34582554 [TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation. Huang J; Huang S; Ma Z; Lin X; Li X; Huang X; Wang J; Ye W; Li Y; He D; Yang M; Pan J; Ling Q; Li F; Mao S; Wang H; Wang Y; Jin J Thromb Haemost; 2021 Feb; 121(2):192-205. PubMed ID: 32961571 [TBL] [Abstract][Full Text] [Related]
20. Effects of cytokines on platelet production from blood and marrow CD34+ cells. Norol F; Vitrat N; Cramer E; Guichard J; Burstein SA; Vainchenker W; Debili N Blood; 1998 Feb; 91(3):830-43. PubMed ID: 9446643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]